Fiche centre
Axiom Clinical Research of Florida
Tampa — United States
Essais liés8clinical trials
VilleTampalocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT02637856
Essais cliniques associés
8| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| JNJ-63733657 | Alzheimer | Phase 2 | NCT04619420 | Autonomy — A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease | TERMINATED |
| Ocrelizumab | SEP | Phase 3 | NCT02637856 | A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) | COMPLETED |
| Spectris™ AD - Active | Alzheimer | Non applicable | NCT05637801 | A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study) | COMPLETED |
| Donanemab | Alzheimer | Phase 3 | NCT04437511 | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) | ACTIVE_NOT_RECRUITING |
| Interferon beta-1a | SEP | Phase 3 | NCT01247324 | A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis | COMPLETED |
| Atogepant | Migraine | Phase 3 | NCT03777059 | 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine | COMPLETED |
| Atogepant | Migraine | Phase 3 | NCT03939312 | Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine | COMPLETED |
| Cenerimod 0.5 mg | Lupus | Phase 2 | NCT03742037 | Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus | COMPLETED |